Amneal Pharmaceuticals announced that the FDA has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials. The product is eligible for Competitive Generic… read more.
National Institute for Health and Care (NICE) has recommended mirvetuximab soravtansine (Elahere; AbbVie) for NHS use, marking the first new targeted therapy for platinum-resistant ovarian cancer in over… read more.
The Lancet Oncology Commission warns the shortfall, driven by rising cancer rates and workforce gaps, will place significant strain on health systems worldwide, with the largest shortages expected in nursing and… read more.
The path to wiping out cervical cancer looks increasingly clear – at least for high-income countries with strong uptake of the human papillomavirus (HPV) vaccine and cervical screening…. read more.
Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at… read more.
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing… read more.
Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated Cochrane review finds. This is a shift from… read more.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that final data from the Phase 3 AcceleRET-Lung clinical trial of… read more.
At the 2026 ASCO Annual Meeting, Boehringer Ingelheim presented new data from across its oncology clinical development program, including patient-reported outcomes (PROs) for HERNEXEOS® (zongertinib tablets) in HER2… read more.
Pfizer Inc. announced positive topline results from the Phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an… read more.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Mekinist. The marketing… read more.
The digital transformation of pathology is opening up new possibilities for cancer diagnosis. Today’s artificial intelligence (AI) techniques now go far beyond mere automation: they make it possible… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
